RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $227.27 million. The enterprise value is $21.46 million.
Important Dates
The last earnings date was Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 41.40 million shares outstanding. The number of shares has increased by 3.18% in one year.
| Current Share Class | 41.40M |
| Shares Outstanding | 41.40M |
| Shares Change (YoY) | +3.18% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 5.36% |
| Owned by Institutions (%) | 86.11% |
| Float | 37.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.79 |
| Forward PS | 1.67 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.20, with a Debt / Equity ratio of 0.04.
| Current Ratio | 10.20 |
| Quick Ratio | 8.78 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,459.13 |
Financial Efficiency
Return on equity (ROE) is -17.06% and return on invested capital (ROIC) is -93.15%.
| Return on Equity (ROE) | -17.06% |
| Return on Assets (ROA) | -11.21% |
| Return on Invested Capital (ROIC) | -93.15% |
| Return on Capital Employed (ROCE) | -20.01% |
| Weighted Average Cost of Capital (WACC) | 10.54% |
| Revenue Per Employee | $276,523 |
| Profits Per Employee | -$101,167 |
| Employee Count | 461 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.00 |
Taxes
In the past 12 months, RxSight has paid $54,000 in taxes.
| Income Tax | 54,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.58% in the last 52 weeks. The beta is 1.23, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -60.58% |
| 50-Day Moving Average | 6.93 |
| 200-Day Moving Average | 8.72 |
| Relative Strength Index (RSI) | 29.48 |
| Average Volume (20 Days) | 688,276 |
Short Selling Information
The latest short interest is 5.57 million, so 13.47% of the outstanding shares have been sold short.
| Short Interest | 5.57M |
| Short Previous Month | 5.06M |
| Short % of Shares Out | 13.47% |
| Short % of Float | 15.05% |
| Short Ratio (days to cover) | 7.37 |
Income Statement
In the last 12 months, RxSight had revenue of $127.48 million and -$46.64 million in losses. Loss per share was -$1.14.
| Revenue | 127.48M |
| Gross Profit | 98.18M |
| Operating Income | -55.35M |
| Pretax Income | -46.58M |
| Net Income | -46.64M |
| EBITDA | -52.02M |
| EBIT | -55.35M |
| Loss Per Share | -$1.14 |
Full Income StatementBalance Sheet
The company has $217.88 million in cash and $10.83 million in debt, with a net cash position of $207.05 million or $5.00 per share.
| Cash & Cash Equivalents | 217.88M |
| Total Debt | 10.83M |
| Net Cash | 207.05M |
| Net Cash Per Share | $5.00 |
| Equity (Book Value) | 267.30M |
| Book Value Per Share | 6.46 |
| Working Capital | 251.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.57 million and capital expenditures -$4.01 million, giving a free cash flow of -$21.58 million.
| Operating Cash Flow | -17.57M |
| Capital Expenditures | -4.01M |
| Depreciation & Amortization | 3.32M |
| Net Borrowing | -20,000 |
| Free Cash Flow | -21.58M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
Gross margin is 77.02%, with operating and profit margins of -43.42% and -36.59%.
| Gross Margin | 77.02% |
| Operating Margin | -43.42% |
| Pretax Margin | -36.54% |
| Profit Margin | -36.59% |
| EBITDA Margin | -40.81% |
| EBIT Margin | -43.42% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.18% |
| Shareholder Yield | -3.18% |
| Earnings Yield | -20.41% |
| FCF Yield | -9.45% |
Analyst Forecast
The average price target for RxSight is $9.44, which is 71.95% higher than the current price. The consensus rating is "Hold".
| Price Target | $9.44 |
| Price Target Difference | 71.95% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 4.73 and a Piotroski F-Score of 2.
| Altman Z-Score | 4.73 |
| Piotroski F-Score | 2 |
